What's at stake: Dual-listed cancer diagnostics company Pacific Edge has raised $36.1m from investors after a four-year battle to regain Medicare reimbursement for its Cxbladder tests.
Background: Coverage by Medicare administrative contractor Novitas was ended in April last year after the lengthy process for a new Local Coverage Determination. Last month Novitas released a new LCD providing coverage for Pacific Edge tests for intermediate-risk haematuria patients.
Main players: Pacific Edge, Novitas, Medicare, American Urological Association.
There’s no shortage of quotes around hope, including the famous idiom “hope springs eternal”, meaning people continue to be optimistic even when the odds are stacked against them.
It’s a shortened version of a line from “An Essay of Man” by English poet Alexander Pope which read:
Sign up to get the latest stories and insights delivered to your inbox – free, every day.
Key points
What's at stake: Dual-listed cancer diagnostics company Pacific Edge has raised $36.1m from investors after a four-year battle to regain Medicare reimbursement for its Cxbladder tests.
Background: Coverage by Medicare administrative contractor Novitas was ended in April last year after the lengthy process for a new Local Coverage Determination. Last month Novitas released a new LCD providing coverage for Pacific Edge tests for intermediate-risk haematuria patients.
Main players: Pacific Edge, Novitas, Medicare, American Urological Association.
